[The use of verapamil for the prevention of relapses of affective and schizoaffective psychoses].
Efficiency of verapamil was studied in secondary prophylaxis of phasic affective disorders, 50 patients with affective and schizoaffective psychoses were treated during 2 years. Daily dose of verapamil was 80-320 mg (average dose-240 mg). Three groups were formed. Group 1 (10 patients) included patients which didn't receive any prophylactic therapy during previous 2 years. In group 2 (25 patients) and 3 (15 patients) verapamil was administrated after 2 years of prophylactic therapy with either lithium carbonate or carbamazepine, respectively. Clear prophylactic activity of verapamil was observed. There was preference of its reducing effect on the depressive phases. The data obtained and good tolerance of verapamil evidence for effectiveness of prolonged administration of this preparation as a drug with antirelapsed properties.
V A
VA
Raiushkin
D000328:Adult; D000341:Affective Disorders, Psychotic / Q000517:prevention & control*; D000368:Aged; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011618:Psychotic Disorders / Q000517:prevention & control*; D055502:Secondary Prevention; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000627:therapeutic use*; D014700:Verapamil / Q000627:therapeutic use*
D014665:Vasodilator Agents; D014700:Verapamil